Program - Pharmacometrics Japan Conference 2020

Program

Day 1, January 22nd, Wednesday

09:00

Registration

09:30

Welcome address

Yusuke Tanigawara　(Keio University)

Plenary Lecture　 (Chair: Yusuke Tanigawara)

10:00

The Use of Precision Dosing to Inform Personalized Medicine

Larry Lesko　(University of Florida)

Short Poster Presentations　 (Chair: Kimio Terao)

11:00

All poster presenters　

　

12:00

Lunch & poster walk

Keynote Speech　 (Chair: Peter Bonate)

14:00

The International Society of Pharmacometrics

Justin Wilkins　(ISoP)

Session 1. Clinical Pharmacometrics　 (Chairs: Peiming Ma and Keizo Fukushima)

14:30

Model-based dosing in clinical practice

Birgit CP Koch　(Erasmus MC)

15:00

Pharmacometric modeling and simulation of osteoporosis drug: from biomarker models to fracture risk prediction

Hidefumi Kasai　(Keio University)

15:30

Break

16:00

Population pharmacokinetics of vancomycin in pediatric patients with various degrees of renal function

Thitima Wattanavijitkul　(Chulalongkorn University)

16:30

Prediction of within-subject variability using population approaches and its application to demonstrate highly variable drug

Hwi-yeol Yun　(Chungnam National University)

Oral Presentation 1. Clinical Pharmacometrics　 (Chairs: Mark Rogge and Birgit CP Koch)

17:00

Pharmacometric Time-to-Event (TTE) Modeling of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients Sohail Aziz　(Universiti Sains Malaysia)

17:15

Application of Exposure-Response Analysis to Lenvatinib Post-marketing Trial for Dose Optimization Seiichi Hayato　(Eisai Co. Ltd.)

17:30

Pharmacodynamic analysis of lenvatinib safety in thyroid cancer patients using post-marketing surveillance (PMS) data Yuki Otani　(Keio University School of Medicine)

17:45

Population pharmacokinetics and pharmacodynamics of artesunate in patients with drug-sensitive and drug-resistant P. falciparum malaria: a semi-mechanistic modelling approach Thanaporn Wattanakul　(Mahidol University)

　

18:30

Reception　(Ticket required)

Day 2, January 23rd, Thursday

Session 2. Model-Informed Drug Development (MIDD)　 (Chairs: So Miyoshi and Mayumi Hasegawa)

09:30

The Age of Enlightenment of Model-Informed Drug Development (MIDD)

Daniele Ouellet　(Pfizer)

10:00

Model-Based Frameworks of CNS Biomarkers Inform Critical Early Decisions

Mark Rogge　(Takeda)

10:30

Recent trends in drug development and use of pharmacometrics in China

Peiming Ma　(GlaxoSmithKline)

11:00

Quantitative Modeling and Simulation in PMDA: Activity and Perspective

Shinichi Kijima　(PMDA)

　

11:30

Lunch & poster walk　

Oral Presentation 2. Model-Informed Drug Development (MIDD)　 (Chairs: Daniele Ouellet and Toshihiro Wajima)

13:30

Impact of Japanese Ethnicity on the Pharmacokinetic Profile of Monoclonal Antibody Drugs Yuki Iwaki　(Janssen Pharmaceutical K.K.)

13:45

Dapagliflozin Exposure–Response in Japanese vs Non-Japanese Patients with Type 1 Diabetes Victor Sokolov　(M&S Decisions LLC)

14:00

The application of Bayesian statistics (Markov Chain Monte Carlo) in population pharmacokinetics – Case example from Industry Kanji Komatsu　(Astellas Pharma Inc.)

14:15

Analysis of long-term progression of Parkinson's disease by SReFT (Statistical Restoration of Fragmented Time course) which is a significant expansion of population pharmacokinetic analysis Ryota Jin　(Chiba University)

　

14:30

Break
Poster removal　

Session 3. Methodology　 (Chair: Kanji Komatsu)

15:00

Application of Extreme Value Theory in the Analysis of Safety Data

Peter Bonate　(Astellas)

Oral Presentation 3. Methodology　 (Chairs: Hidefumi Kasai and Osamu Takenaka)

15:30

The phantom of plasma protein binding in preclinical drug development Dong-Seok Yim　(The Catholic University of Korea)

15:45

Identifying systematic bias in model predictions Shamin Mohd Saffian　(The National University of Malaysia)

16:00

Indirect pharmacodynamic model for diverse drug responses with circadian removal Vivaswath Ayyar　(State University of New York at Buffalo)

　

16:20

Closing remark Yusuke Tanigawara　(Keio University)

16:40

Adjourn

Poster presentations

P-01

Dose optimization of meropenem through population pharmacokinetic modelling in Pakistani patients Muhammad Usman　(University of Veterinary and Animal Sciences)

P-02

Population pharmacokinetic model of vancomycin based on cystatin C in multi-ethnic Malaysian patients Nor Asyikin Mohd Tahir　(Universiti Kebangsaan Malaysia)

P-03

Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis Waroonrat Sukarnjanaset　(Chulalongkorn University)

P-04

Population Pharmacokinetics and Pharmacodynamics of Voriconazole: Serum albumin based target optimization for invasive aspergillosis patients Prawat Chantharit　(Keio University School of Medicine)

P-05

Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects Areewan Sujintawong　(Mahidol University)

P-06

Drug development for the treatment, control and elimination of Onchocerciasis: A pooled population pharmacokinetic analysis of emodepside (BAY 44-4400) in healthy subjects Frauke Assmus　(Mahidol University)

P-07

Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Drug Development Hiroki Koshimichi　(Shionogi & Co., Ltd)

P-08

Clinical and Genetic Determinants of Nevirapine Pharmacokinetic Variability in Malaysian Adults with HIV infection Suzana Mustafa　(Ministry of Health Malaysia)

P-09

Individual dosing of Efavirenz Based on Pharmacogenomics and Population Pharmacokinetics in Thai HIV-infected Patients and HIV/TB co-infected patients Piyawat Chaivichacharn　(Chiangmai university)

P-10

Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice Hiroyuki Iida　(Ono Pharmaceutical Co., Ltd.)

P-11

Population PK guided new dosage and regimen for ceritinib Takeshi Tajima　(Novartis Pharma K.K.)

P-12

Population Pharmacokinetics Modeling of Cyclosporine among Malaysian Renal Transplant Patients Orwa Albitar　(Universiti Sains Malaysia)

P-13

Population Pharmacokinetics Analysis of Tacrolimus in Thai Adult Kidney Transplantation Patients Suthida Boonsom　(University of Phayao)

P-14

External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients Ranita Kirubakaran　(St Vincent’s Clinical School, UNSW Sydney)

P-15

Description of Irbesartan distribution using delay differential equations and the impact of time delay on Irbesartan pharmacokinetics and pharmacodynamics Eleni Karatza　(National and Kapodistrian University of Athens)

P-16

Development of population pharmacokinetics models for methadone and its racemate in Malaysian MMT patients: A non-parametric approach Nurfadhlina Musa　(Universiti Sains Malaysia)

P-17

Population pharmacokinetics of blonanserin after application of transdermal patch Atsushi Kitamura　(Sumitomo Dainippon Pharma Co., Ltd.)

P-18

The evaluation of drug-herbal medicine (duloxetine-propolis) interaction with population pharmacokinetics approach JUNG-WOO CHAE　(Chungnam National University)

P-19

Physiological Based Pharmacokinetics Modeling of Methylphenidate Exposure with Altered CES1 Function Jingcheng Xiao　(University of Michigan)

P-20

Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid Taniya Paiboonvong　(Rangsit University)

P-21

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies Shakir Adeyinka Atoyebi　(Obafemi Awolowo University)

P-22

Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to pharmacodynamic responses in liver: a systems PK/PD model to predict corticosteroid actions Vivaswath Ayyar　(State University of New York at Buffalo)

P-23

(withdrawn)

P-24

(withdrawn)

P-25

Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for platelet count profiles after administration of lusutrombopag Ryosuke Shimizu　(Shionogi & Co., Ltd)

P-26

Utilizing Machine Learning in Analysis of Megatrials – A Combined Analysis of the OASIS-5 and -6 Trials Using Individual Patient Data Hideki Yoshioka　(Chiba University)

P-27

Development of Rheumatoid arthritis QSP model capturing mechanistic pathways and clinical read-outs to enable simulation of novel targets and trial Maithreye Rengaswamy　(Vantage Research)